These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23558905)

  • 1. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
    Lee SM; Lee WS; Shin HJ; Lee JJ; Sohn SK; Moon JH; Eom HS; Won JH; Lee KH; Lee JH; Kim DY; Yoon SS; Kim I; Jung CW; Kim SJ; Kim H; Lee JH; Ryoo HM; Lee GW; Kim SH; Mun YC; Kim MK; Joo YD;
    Ann Hematol; 2013 Aug; 92(8):1101-10. PubMed ID: 23558905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
    Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of 71 adult acute lymphoblastic leukemia].
    Yoshida M; Kurata H; Tsunoda S; Iwama A; Suzuki T; Akutsu M; Imagawa S; Tsunoda J; Furukawa Y; Komatsu N
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1827-33. PubMed ID: 8379676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
    Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
    Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.
    Wiernik PH; Dutcher JP; Paietta E; Gucalp R; Markus S; Weinberg V; Azar C; Garl S; Benson L
    Leukemia; 1993 Aug; 7(8):1236-41. PubMed ID: 8350624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period.
    Ferrari A; Annino L; Crescenzi S; Romani C; Mandelli F
    Leukemia; 1995 Oct; 9(10):1643-7. PubMed ID: 7564503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The programmed therapy of acute lymphoblastic leukemia in adults].
    Isaev VG; Savchenko VG; Kucher RA; Abakumov EM; Parovichnikova EN
    Ter Arkh; 1992; 64(8):82-7. PubMed ID: 1440405
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
    Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
    Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia.
    Todeschini G; Meneghini V; Pizzolo G; Cassibba V; Ambrosetti A; Veneri D; Nadali G; Zanotti R; Tecchio C; Perona G
    Leukemia; 1994 Mar; 8(3):376-81. PubMed ID: 8127142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study.
    Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F
    Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.
    Hunault-Berger M; Milpied N; Bernard M; Jouet JP; Delain M; Desablens B; Sadoun A; Guilhot F; Casassus P; Ifrah N
    Leukemia; 2001 Jun; 15(6):898-902. PubMed ID: 11417474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee KH; Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Kim WK; Lee JS; Seo EJ; Jang S; Park CJ; Chi HS
    Leukemia; 2005 Sep; 19(9):1509-16. PubMed ID: 16034462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.